Selected research
Industry Research
End-Stage Renal Disease (ESRD) Drugs Industry Research Report 2026
Market perspective
The global End-Stage Renal Disease (ESRD) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for End-Stage Renal Disease (ESRD) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for End-Stage Renal Disease (ESRD) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of End-Stage Renal Disease (ESRD) Drugs include Novartis AG, Merck & Co Inc, VESSL Therapeutics Ltd, Prolong Pharmaceuticals LLC and CTI BioPharma Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global End-Stage Renal Disease (ESRD) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
End-Stage Renal Disease (ESRD) Drugs Market by Company
Novartis AG
Merck & Co Inc
VESSL Therapeutics Ltd
Prolong Pharmaceuticals LLC
CTI BioPharma Corp
End-Stage Renal Disease (ESRD) Drugs Segment by Type
Sanguinate
Tesidolumab
Calcium Succinate
Mk-3866
Pacritinib
Others
End-Stage Renal Disease (ESRD) Drugs Segment by Application
ICU
Hospital
Clinic
Others
End-Stage Renal Disease (ESRD) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End-Stage Renal Disease (ESRD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of End-Stage Renal Disease (ESRD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End-Stage Renal Disease (ESRD) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of End-Stage Renal Disease (ESRD) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of End-Stage Renal Disease (ESRD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sanguinate
- Tesidolumab
- Calcium Succinate
- Mk-3866
- Pacritinib
- Others
Applications
- ICU
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co Inc
- VESSL Therapeutics Ltd
- Prolong Pharmaceuticals LLC
- CTI BioPharma Corp
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size (2021-2032)
- 2.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales (2021-2032)
- 2.2.3 Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (2021-2032)
- 2.3 End-Stage Renal Disease (ESRD) Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Sanguinate
- 2.3.3 Tesidolumab
- 2.3.4 Calcium Succinate
- 2.3.5 Mk-3866
- 2.3.6 Pacritinib
- 2.3.7 Others
- 2.4 End-Stage Renal Disease (ESRD) Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 ICU
- 2.4.3 Hospital
- 2.4.4 Clinic
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global End-Stage Renal Disease (ESRD) Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global End-Stage Renal Disease (ESRD) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Product Type & Application
- 3.8 Global Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Established Date
- 3.9 Global End-Stage Renal Disease (ESRD) Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co Inc
- 4.2.1 Merck & Co Inc Company Information
- 4.2.2 Merck & Co Inc Business Overview
- 4.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
- 4.2.5 Merck & Co Inc Recent Developments
- 4.3 VESSL Therapeutics Ltd
- 4.3.1 VESSL Therapeutics Ltd Company Information
- 4.3.2 VESSL Therapeutics Ltd Business Overview
- 4.3.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
- 4.3.5 VESSL Therapeutics Ltd Recent Developments
- 4.4 Prolong Pharmaceuticals LLC
- 4.4.1 Prolong Pharmaceuticals LLC Company Information
- 4.4.2 Prolong Pharmaceuticals LLC Business Overview
- 4.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
- 4.4.5 Prolong Pharmaceuticals LLC Recent Developments
- 4.5 CTI BioPharma Corp
- 4.5.1 CTI BioPharma Corp Company Information
- 4.5.2 CTI BioPharma Corp Business Overview
- 4.5.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
- 4.5.5 CTI BioPharma Corp Recent Developments
5 Global End-Stage Renal Disease (ESRD) Drugs Market Scenario by Region
- 5.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021-2032
- 5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021-2026
- 5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2027-2032
- 5.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2021-2032
- 5.3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2021-2026
- 5.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2027-2032
- 5.4 North America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
- 5.4.1 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
- 5.4.3 North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
- 5.5.1 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
- 5.5.3 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
- 5.7.1 South America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
- 5.7.3 South America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
- 6.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
- 6.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
- 7.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
- 7.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 End-Stage Renal Disease (ESRD) Drugs Value Chain Analysis
- 8.1.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 End-Stage Renal Disease (ESRD) Drugs Production Mode & Process
- 8.2 End-Stage Renal Disease (ESRD) Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 End-Stage Renal Disease (ESRD) Drugs Distributors
- 8.2.3 End-Stage Renal Disease (ESRD) Drugs Customers
9 Global End-Stage Renal Disease (ESRD) Drugs Analyzing Market Dynamics
- 9.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
- 9.2 End-Stage Renal Disease (ESRD) Drugs Industry Drivers
- 9.3 End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges
- 9.4 End-Stage Renal Disease (ESRD) Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst